Roberts SK - Search Results

1

Safety, Pharmacokinetics, and Pharmacodynamics of the Oral TLR8 Agonist Selgantolimod in Chronic Hepatitis B.

Gane EJ, Kim HJ, Visvanathan K, Kim YJ, Nguyen AH, Wallin JJ, Chen DY, McDonald C, Arora P, Tan SK, Gaggar A, Roberts SK, Lim YS. Gane EJ, et al. Among authors: roberts sk. Hepatology. 2021 Oct;74(4):1737-1749. doi: 10.1002/hep.31795. Epub 2021 Sep 14. Hepatology. 2021. PMID: 33704806 Clinical Trial.

2

Robust antiviral activity of R1626, a novel nucleoside analog: a randomized, placebo-controlled study in patients with chronic hepatitis C.

Roberts SK, Cooksley G, Dore GJ, Robson R, Shaw D, Berns H, Hill G, Klumpp K, Najera I, Washington C. Roberts SK, et al. Hepatology. 2008 Aug;48(2):398-406. doi: 10.1002/hep.22321. Hepatology. 2008. PMID: 18553458 Clinical Trial.

3

Impact of high-dose peginterferon alfa-2A on virological response rates in patients with hepatitis C genotype 1: a randomized controlled trial.

Roberts SK, Weltman MD, Crawford DH, McCaughan GW, Sievert W, Cheng WS, Rawlinson W, Desmond PV, Marks PS, Yoshihara M, Rizkalla B, Depamphilis JK, Dore GJ; Chariot Study Group. Roberts SK, et al. Hepatology. 2009 Oct;50(4):1045-55. doi: 10.1002/hep.23130. Hepatology. 2009. PMID: 19676125 Clinical Trial.

4

Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis.

Bruno S, Shiffman ML, Roberts SK, Gane EJ, Messinger D, Hadziyannis SJ, Marcellin P. Bruno S, et al. Among authors: roberts sk. Hepatology. 2010 Feb;51(2):388-97. doi: 10.1002/hep.23340. Hepatology. 2010. PMID: 19918980 Clinical Trial.

5

Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial.

Gane EJ, Roberts SK, Stedman CA, Angus PW, Ritchie B, Elston R, Ipe D, Morcos PN, Baher L, Najera I, Chu T, Lopatin U, Berrey MM, Bradford W, Laughlin M, Shulman NS, Smith PF. Gane EJ, et al. Among authors: roberts sk. Lancet. 2010 Oct 30;376(9751):1467-75. doi: 10.1016/S0140-6736(10)61384-0. Epub 2010 Oct 14. Lancet. 2010. PMID: 20951424 Clinical Trial.

6

Virological response is associated with decline in hemoglobin concentration during pegylated interferon and ribavirin therapy in hepatitis C virus genotype 1.

Sievert W, Dore GJ, McCaughan GW, Yoshihara M, Crawford DH, Cheng W, Weltman M, Rawlinson W, Rizkalla B, Depamphilis JK, Roberts SK; CHARIOT Study Group. Sievert W, et al. Among authors: roberts sk. Hepatology. 2011 Apr;53(4):1109-17. doi: 10.1002/hep.24180. Hepatology. 2011. PMID: 21480317 Clinical Trial.

7

Safety of peginterferon alfa-2a plus ribavirin in a large multinational cohort of chronic hepatitis C patients.

Lee SS, Roberts SK, Berak H, Dusheiko GM, Harley HA, Gane EJ, Husa P, Horsmans YJ, Hadziyannis SJ, Jenny Heathcote E, Messinger D, Tatsch F, Han KH, Ferenci P. Lee SS, et al. Among authors: roberts sk. Liver Int. 2012 Sep;32(8):1270-7. doi: 10.1111/j.1478-3231.2012.02819.x. Epub 2012 May 24. Liver Int. 2012. PMID: 22621707 Clinical Trial.

8

Vitamin D status does not predict sustained virologic response or fibrosis stage in chronic hepatitis C genotype 1 infection.

Kitson MT, Dore GJ, George J, Button P, McCaughan GW, Crawford DH, Sievert W, Weltman MD, Cheng WS, Roberts SK. Kitson MT, et al. Among authors: roberts sk. J Hepatol. 2013 Mar;58(3):467-72. doi: 10.1016/j.jhep.2012.11.017. Epub 2012 Nov 23. J Hepatol. 2013. PMID: 23183524 Free article.

9

ITPA genotype protects against anemia during peginterferon and ribavirin therapy but does not influence virological response.

Holmes JA, Roberts SK, Ali RJ, Dore GJ, Sievert W, McCaughan GW, Crawford DH, Cheng WS, Weltman MD, Bonanzinga S, Visvanathan K, Sundararajan V, Desmond PV, Bowden DS, Matthews GV, Thompson AJ; CHARIOT Study Group. Holmes JA, et al. Among authors: roberts sk. Hepatology. 2014 Jun;59(6):2152-60. doi: 10.1002/hep.27022. Epub 2014 Apr 25. Hepatology. 2014. PMID: 24449403

10

Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C-related liver disease and costs in Australia.

Sievert W, Razavi H, Estes C, Thompson AJ, Zekry A, Roberts SK, Dore GJ. Sievert W, et al. Among authors: roberts sk. J Gastroenterol Hepatol. 2014 Aug;29 Suppl 1:1-9. doi: 10.1111/jgh.12677. J Gastroenterol Hepatol. 2014. PMID: 25055928

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

285 results

Search Page